News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 109–144
- Matches
- 306
- Sources here
- 22
- Companies here
- 8
Search results
Stored financial headlines
Active search
306 matching headlines
Ticker or company: CTAMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Embecta Corp. (EMBC): Deeply Undervalued Global Medical Device Company
Embecta Corp. (EMBC), a global medical device company specializing in diabetes care, is highlighted as a potentially undervalued opportunity. Despite operating in a defensive healthcare sector with stable demand, EMBC trades at attractive valuation levels, boasting strong cash generation, resilient profitability, and an improving …
EMBC
main company
Sharemaestro market context
New activity signal
52 weeks -63.1%
Will These 3 Insurance Stocks Insure a Q2 Earnings Beat?
As second-quarter 2026 earnings continue to roll in, the insurance sector is emerging as one of the early bright spots. Industry leaders Marsh, AON and Hartford have already cleared the bar, reporting results that topped expectations and offering investors a constructive read on the …
OSG
main company
Sharemaestro market context
Price below Trend Line
39 weeks -45.4%
Levi & Korsinsky Reminds Embecta Corp. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 17, 2026 - EMBC
Levi & Korsinsky, LLP is reminding Embecta Corp. (NASDAQ: EMBC) investors of a pending class action lawsuit with a lead plaintiff deadline of August 17, 2026. The lawsuit alleges that Embecta made misleading statements regarding its fiscal year 2026 revenue guidance and U.S. pen …
EMBC
main company
Sharemaestro market context
New activity signal
52 weeks -63.1%
Kaplan Fox Deadline Alert: Embecta Corp. (NASDAQ: EMBC) Investors Have Until August 17, 2026 to Seek a Lead Plaintiff Role
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit stems from a significant drop in Embecta's stock price after the …
EMBC
main company
Sharemaestro market context
New activity signal
52 weeks -63.1%
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A
Bernstein Liebhard LLP has filed a securities class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased shares between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made false and misleading statements about its business, leading …
EMBC
main company
Sharemaestro market context
New activity signal
52 weeks -63.1%
Empery Asset Management (CLRB) discloses 9.99% beneficial stake via stock and warrants
Empery Asset Management, LP and Ryan M. Lane have reported a beneficial ownership of 9.99% in Cellectar Biosciences, Inc. (CLRB) through a Schedule 13G filing. This stake includes 864,090 shares, with 674,485 shares issuable upon the exercise of warrants, all subject to a 9.99% …
CLRB
main company
Sharemaestro market context
Price below Trend Line
52 weeks -46.7% · Next-week setup negative 44.8%
EMBC UPCOMING DEADLINE : The Gross Law Firm Alerts Embecta Corp. Stockholders of Securities Class Action - Contact the Firm
The Gross Law Firm has issued a notice to shareholders of Embecta Corp. (NASDAQ: EMBC) regarding a securities class action lawsuit. The lawsuit alleges that Embecta made misleading statements about its financial performance, particularly concerning its pen needle business, leading to a significant stock …
EMBC
main company
Sharemaestro market context
New activity signal
52 weeks -63.1%
Octave Specialty Group to Report Q2 Earnings: What to Expect
Octave Specialty Group, Inc. OSG is expected to witness an improvement in its top and bottom lines when it reports second-quarter 2026 results on Aug. 6, after the closing bell. The Zacks Consensus Estimate for OSG's second-quarter revenues is pegged at $81 million, indicating …
OSG
main company
Sharemaestro market context
Price below Trend Line
39 weeks -45.4%
Deadline Alert: Embecta Corp. (EMBC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is reminding investors of Embecta Corp. (EMBC) about an upcoming August 17, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges that Embecta made materially false and misleading statements between November …
EMBC
main company
Sharemaestro market context
New activity signal
52 weeks -63.1%
EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
The Rosen Law Firm reminds investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, of the upcoming August 17, 2026 lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Embecta made misleading statements …
EMBC
main company
Sharemaestro market context
New activity signal
52 weeks -63.1%
Embecta Corp. (EMBC) Faces Securities Class Action Over Insulin Pen Needle Disclosure - Investors with Losses Encouraged to Contact HBSS
Hagens Berman is investigating Embecta Corp. (EMBC) following a securities class action lawsuit alleging the company misrepresented the stability of its insulin pen needle business. The lawsuit claims Embecta's assurances of a "stable" business were false, as it was experiencing significant competitive share loss …
EMBC
main company
Sharemaestro market context
New activity signal
52 weeks -63.1%
Embecta Corp. (NASDAQ:EMBC) Given Consensus Rating of "Reduce" by Analysts
Analysts have issued a consensus "Reduce" rating for Embecta Corp. (NASDAQ:EMBC), with an average 12-month price target of $11, though recent targets have been significantly lowered to $3-$5. The company recently reported weaker-than-expected Q1 earnings, missing EPS estimates and experiencing a 14.4% year-over-year revenue …
EMBC
main company
Sharemaestro market context
New activity signal
52 weeks -63.1%
Cellectar Biosciences, Inc. Revenue Breakdown – NASDAQ:CLRB
This article provides a revenue breakdown for Cellectar Biosciences, Inc. (NASDAQ: CLRB) as presented on TradingView. It offers an overview of the company's financial data, including statements, statistics, dividends, earnings, and segment performance. The information is sourced from various financial data providers like ICE …
CLRB
main company
Sharemaestro market context
Price below Trend Line
52 weeks -46.7% · Next-week setup negative 44.8%
Embecta Corp. (NASDAQ: EMBC) outlines Owen Mumford deal terms and pro forma results
Embecta Corp. has outlined the detailed terms and pro forma financial results of its acquisition of Owen Mumford Holdings Limited, which was completed on May 15, 2026. The deal involved an upfront cash payment of £126.0 million ($166.1 million) and potential earn-out payments of …
EMBC
main company
Sharemaestro market context
New activity signal
52 weeks -63.1%
Embecta (EMBC) Stock Drop: Robbins LLP Reminds Investors of Class Action and Urges Shareholders Who Lost Money to Contact the Firm
Robbins LLP has filed a securities class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased shares between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta misled investors about its financial outlook, particularly its pen needle …
EMBC
main company
Sharemaestro market context
New activity signal
52 weeks -63.1%